CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Arthur Kuan, the company's Chairman & CEO, is scheduled for a fireside chat on September 6, 2024, at 10:45 am ET in New York, NY.

CG Oncology focuses on developing a potential backbone bladder-sparing therapeutic for bladder cancer patients. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.cgoncology.com. A replay of the webcast will be available for approximately 90 days after the live presentation concludes.

News Market Reaction – CGON

+0.55%

1 alert

+0.55% News Effect

On the day this news was published, CGON gained 0.55%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts

Media
Sarah Connors
VP, Communications and Patient Advocacy
(508) 654-2277
sarah.connors@cgoncology.com

Investor Relations
Laurence Watts
New Street IR
(619) 916-7620
IR@cgoncology.com

FAQ

When is CG Oncology (CGON) participating in the Morgan Stanley Healthcare Conference?

CG Oncology (CGON) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, with a fireside chat scheduled for 10:45 am ET in New York, NY.

Who will represent CG Oncology (CGON) at the Morgan Stanley Healthcare Conference?

Arthur Kuan, the Chairman & Chief Executive Officer of CG Oncology (CGON), will represent the company at the Morgan Stanley Healthcare Conference.

How can investors access CG Oncology's (CGON) presentation at the Morgan Stanley conference?

Investors can access the live audio webcast of CG Oncology's (CGON) presentation from the Investor Relations section of the company's website at www.cgoncology.com.

What is CG Oncology's (CGON) main focus in drug development?

CG Oncology (CGON) is focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer.

How long will the webcast replay of CG Oncology's (CGON) presentation be available?

The webcast replay of CG Oncology's (CGON) presentation will be available for approximately 90 days after the conclusion of the live presentation.